New Delhi.
Company hian a hmain calcium chloride dihydrate solution 100 mmol/L concentration siam leh hralh chhuah turin dilna an thehlut tawh a, hei hi “calcium replacement therapy in continuous renal replacement therapy (CRRT), continuous low-efficiency (daily) dialysis (CLED) leh therapeutic plasma exchange (TPE) with citrate anticoagulation.He product hi puitling leh naupangte” tih leh phase III leh phase IV clinical trial-a tel loh chhante a sawi bawk.
Committee chuan Europe ram Portugal, United Kingdom, Brazil, Switzerland, France leh Denmark-ah te pawh phalna pek a nih thu an sawi.
Compound calcium chloride dihydrate chu CaCl2 2H2O a ni a, hei hi calcium chloride a ni a, calcium chloride unit khatah tui molecule pahnih a awm a ni. White crystalline substance a ni a, tuiah pawh a inthiar awlsam a, hygroscopic a ni a, chu chu boruak atanga tui lo chhuak thei a ni.
Calcium chloride dihydrate hi methanol-a chitin a hmin chuan solvent system atan hman theih a ni. Chitin crystal structure tihchhiatna kawngah hmun pawimawh tak a chang a, chemistry lamah pawh hmanna hrang hrang a nei a ni.
May 20, 2025-a SEC Nephrology meeting neihah khan panel chuan “calcium replacement therapy in continuous renal replacement therapy (CRRT), continuous plasma low-efficiency (daily) dialysis (SLEDD), leh therapeutic exchange-a hman tur 100 mmol/L calcium chloride dihydrate infusion solution siam leh hralh phalsak tura rawtna chu an enfiah a (TPE) hmanga citrate anticoagulation hman a ni.
Chipchiar taka sawiho a nih hnuah, committee chuan phalna pekna tur basis bakah, phase III clinical trial data leh damdawi pawmtu ram atanga post-marketing surveillance data te chu committee-ah thehluh a, ngaihtuah belh turin a rawt a ni.
Heng bakah hian chhiar la: CDSCO Group chuan Sanofi-a Myozyme-a Updated Labeling a pawm a, Regulatory Review a Dil
Dr. Divya Kolin hi PharmD zir chhuak a ni a, clinical leh hospital lama tawnhriat ngah tak a nei a, diagnostic leh therapeutic skill tha tak a nei bawk. Mysore Medical College leh Research Institute-a oncology department-ah oncology pharmacist hna a thawk tawh bawk. Tunah hian clinical research leh clinical data management lamah a thawk mek a ni. Kum 2022 January thla aṭang khan Medical Dialogue-ah hna a thawk ṭan a ni.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
ABYSS zirchiannaah chuan myocardial infarction hnua beta-blockers tihtawp chuan thisen sang, heart rate leh cardiovascular adverse events a tisang tih hmuhchhuah a ni: ...